Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [387]

SABCS 2018: Axillary radiotherapy and lymph node surgery yielded comparable 10-year outcomes for patients with breast cancer

SABCS 2018: Axillary radiotherapy and lymph node surgery yielded comparable 10-year outcomes for patients with...

SABCS 2018: Circulating tumour cell count could help choose treatment for metastatic breast cancer patients

SABCS 2018: Circulating tumour cell count could help choose treatment for metastatic breast cancer patients

SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients with DCIS, LCIS, and ADH

SABCS 2018: Low-dose tamoxifen was safe and effective at reducing recurrence and new breast disease for patients...

SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint

SABCS 2018: Phase III KATHERINE clinical trial crossed early reporting boundary and met its primary endpoint

SABCS 2018: Delaying adjuvant chemotherapy associated with worse outcomes for patients with triple-negative breast cancer

SABCS 2018: Delaying adjuvant chemotherapy associated with worse outcomes for patients with triple-negative breast...

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple-negative breast cancer

SABCS 2018: Adjuvant capecitabine did not significantly improve outcomes for patients with early-stage triple...

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Cancer patients show reduced risk of harmful clots while taking direct oral anticoagulants

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

ASH 2018: Concurrent ibrutinib may improve outcomes, reduce toxicity of CAR T-Cell Therapy with JCAR014 for CLL

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of leukaemia

ASH 2018: Tisagenlecleucel continues to show durable remissions in kids and young adults with stubborn form of...

More from ecancer